Home › Head and Neck Squamous Cell Carcinoma › Rhode Island
Head and Neck Squamous Cell Carcinoma clinical trials in Rhode Island
7 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Rhode Island.
Cities in Rhode Island
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537Head and Neck Cancer Study Project in the Geriatric Population
- Rhode Island and The Miriam Hospitals, Providence
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Aug 20, 2026 · NCT06998069FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Site #0132, Providence
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 17, 2026 · NCT06788990Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- Lifespan Cancer Institute at Rhode Island Hospital /ID# 225705, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- Rhode Island Hospital, Providence
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 15, 2025 · NCT06699212Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Rhode Island Hospital, Providence
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.